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On being first in epidemiology
Steven D. Stellman
Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA“Be not the first by whom the New are try'd …”Alexander Pope,
Essay on Criticism
“More I see of it, more this bein' first business looks funny … I bet
yo' twenty-five year from now some fat squirt or other will be
braggin' his head off because he's the first white man to come
through yere with a plug hat on.” The Saga of Andy Burnett
(White, 1947)
“Who's on first?” Abbott and Costello, 1945
In the past few years it has become the fashion for journal articles
to proclaim their finding, however modest, to be first of its kind. Since
few if any epidemiological studies are ever replicated down to the last
detail, this form of self-advertisement is often less impressive than it
appears. What, then, is the importance of establishing primacy for a
particular epidemiological result such as the association between
cigarette smoking and lung cancer? Should we even care who did it
first?
Of course we should, for several reasons. As with all scientific dis-
ciplines, epidemiology has a history rich with useful and important
lessons, but only a complete and accurate history can provide a satis-
factory foundation on which to build a sound practice of public
health. Careful study of our discipline's history provides a perspective
that is otherwise easily overlooked or lost in the day-to-day pursuit of
immediate research goals. Furthermore, we learn from mistakes as
well as achievements, and there are plenty of both available for study.
At first glance, the relationship between cigarette smoking and
lung cancer would seem an unlikely candidate for historical chal-
lenge. It is so well established that one or another aspect is routinely
used as textbook and teaching material (Gordis, 2009). Furthermore,
the founders of the field – e.g., Ernst Wynder, Sir Richard Doll, Austin
Bradford Hill, and Cuyler Hammond – are so well known and their pa-
pers and books so widely reproduced and studied that controversy
regarding the early days scarcely seems possible.
In this issue of Preventive Medicine Alfredo Morabia (Morabia,
2012) dissects a paper (Müller, 1939) that has been described
by later historians and researchers as pathbreaking or seminalE-mail address: sds91@columbia.edu.
0091-7435/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.ypmed.2012.07.010(e.g., Kluger, 1996; Proctor, 2011; USDHHS 1964). In the process, he
finds it methodologically weak even by the standards of its day, and
not even the first paper. Did the historians get it wrong, and if so,
why?
For one thing, professional historians of tobacco and health do
what they do best, namely, ferret out interrelationships, hidden
agendas, and corporate greed and misconduct, against a broad back-
drop of scientific advances in chemistry and toxicology as well as ep-
idemiology. In uncovering and synthesizing thousands of facts into a
comprehensive story, they often take reported epidemiological find-
ings at face value and rarely discuss methodological strengths and
weaknesses at the depth of, say, a grant or manuscript review. They
are adept at exposing industry sponsored studies that were purpose-
fully designed to miss the point or fail completely, but may not be
sensitive to a study's deeper problems. Morabia, by contrast, a prac-
ticing epidemiologist with an international reputation who also
possesses impressive credentials in the history of epidemiology
(Morabia, 2004) is in a unique position to critique Müller's study
from both a historical and a design perspective.
What lessons can we learn from Morabia's critique? Not surpris-
ingly, lessons that are relevant to modern studies. First, there is the
problem of study design. Müller's study is often described as the
first case–control study of smoking and lung cancer. Morabia argues
that it is merely a large case series. This is not a mere quibble over ter-
minology: if correct, there is little basis for assessing the strength of
association between smoking and lung cancer from Müller's data.
Secondly, there is the unproved but dark suggestion of two varieties
of manufactured data: daily consumption of tobacco deduced from
data provided by a proxy respondent or perhaps not at all, and con-
version of stated consumption to grams smoked per day. Inventing
data, of course, if it happened, is by far the larger sin, but the practice
of reporting the weight of tobacco smoked daily, common in France
(Tuyns et al., 1977) as well as Germany, can produce a false illusion
of accurate measurement. It is doubtful whether any of Müller's
smokers knew to the gram how much they smoked per day. More
likely, Müller simply multiplied the number of cigarettes smoked
per day by an assumed average tobacco content. We do not know
the variability of German cigarette weight 75 years ago, but, as
Morabia points out, the weight of tobacco in a modern American cig-
arette can vary by as much as 50% (0.49–0.89 g) (Counts et al., 2004)
and quality control processes in the 1920s and '30s are unlikely to
have been nearly as good as those of modern-day cigarette producers.
Third, although there is no a priori reason to challenge the 30–50
Fig. 1. Yearly citation count for Müller's (1939) paper.
Source: Web of Knowledge©.
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would imply a nicotine dosage as high as 135 mg/day based on
mid-1950s machine yields (Hoffmann and Hoffmann, 1997). This is
more than twice the estimated nicotine dosage of 51 mg/day
inhaled by an American smoker of 50 Marlboro 100 mm filter
cigarettes per day (Counts et al., 2004), and over three times the
nicotine intake measured topographically in our American Health
Foundation studies of smokers of medium-yield cigarettes
(Djordjevic et al., 2000). That would be quite a buzz for many
smokers.
Finally there is the issue of primacy itself. There is an old dictum in
mathematics that a single counter-example can invalidate a theorem.
By identifying the study of Hoffman (1931) that clearly predates
Müller, Morabia has made a strong case, although Samet, in an
accompanying commentary, raises some doubts (Samet, 2012).
History is our collective professional narrative that helps us sort
and organize the countless facts that are the raw data of our profes-
sional lives. Determining whether Müller's study was “the first” is a
necessary step towards historical accuracy, but even more important
is development of an agreed-upon narrative that establishes individ-
ual historical facts as the foundation onwhich public health principles
are built. Most important, however, is how its subsequent impact on
public health evolved. Müller's one paper of importance, published
on the eve of World War II, was picked up by JAMA which in that
era summarized noteworthy papers that had been published in both
domestic and foreign medical journals (Anonymous, 1939). It was
first cited in a 1941 paper on tobacco carcinogenesis in the very first
volume of Cancer Research (Flory, 1941), and then, remarkably, in a
1944 German paper on experimental carcinogenesis (Sjolte, 1944).
It re-emerged in the 1950 classic papers by Doll and Hill (1950) and
Wynder and Graham (1950), and then in a cluster of papers during
the 1950s and early 1960s (Fig. 1). It disappeared for a while, then
re-emerged in the 1980s and has been cited about twice a year
since then a total of 108 times according to the Web of Knowledge©.
Müller, a Nazi, seems to have disappeared into the chasm of World
War II, and his personal influence on public health is limited to this
one publication. Sir Richard Doll, of course, became an iconic figure
in epidemiology as detailed in a recent biography (Keating, 2009),
while Wynder, whose 800 or so papers have been cited in nearly30,000 publications (Stellman, 2006a), went on to found the
American Health Foundation as well as this Journal (Stellman, 2006b).
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